Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
“However, vitamin D has not been formally tested in primary prevention trials, while the NSAID rofecoxib, a COX-2 selective inhibitor, could not be successfully tested because the trial was closed when the drug was withdrawn from the market after an interim safety analysis indicated that the drug was associated with in…”
BackgroundZhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.12.013 · Cited by 2,796
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2069 · Cited by 1,388
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
Authors/Task Force Members (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,336
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O., Weisman, M. H., Jackson, C. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052771 · Cited by 1,329
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
“for colorectal cancer have cast doubt on the suitability of such drugs for long-term use, due to increased risks of adverse cardiovascular events [30,161].”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
“In October 2004, rofecoxib was withdrawn from world markets after a randomized placebo-controlled trial found that in doses of 25 mg/d, it increased rates of cardiovascular events in patients with colorectal polyps.(1) The results were confirmed by several large pharmacoepidemiological studies.”
ResultComplications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
“…trial, comparing 25 mg /day rofecoxib (n = 1287) dose with placebo (n=1299) in 2586 colorectal adenoma patients after 18 months of treatment also reported a greater risk of MI infarctions and ischemic cerebrovascular, congestive heart failure, and cardiac failure events for rofecoxib (131).”
Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., Funahashi, T., Ouchi, N., & Walsh, K. (2005) · Nature Medicine · doi:10.1038/nm1295 · Cited by 982
Celecoxib for the Prevention of Colorectal Adenomatous Polyps
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061652 · Cited by 975
Wang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
“Unexpectedly, the prolonged use of higher doses of COX-2 selective inhibitors is associated with increased thrombotic events in humans (13-15).”
BackgroundThe role of COX‐2 in intestinal inflammation and colorectal cancer
Wang, D., & DuBois, R. N. (2010) · Oncogene · doi:10.1038/onc.2009.421 · Cited by 805
“, 2006) and the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial (Bresalier et al., 2005), were performed and showed that COXIBs prevent recurrence of sporadic adenomas with an increase in cardiovascular events.”
The IL-33/ST2 pathway: therapeutic target and novel biomarker
Kakkar, R., & Lee, R. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2660 · Cited by 794
Flossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Guidelines for Prevention of NSAID-Related Ulcer Complications
and the Practice Parameters Committee of the American College of Gastroenterology, Lanza, F. L., Chan, F. K. L., & Quigley, E. M. M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.115 · Cited by 790
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
“Further studies, conclusively demonstrated that selective COX-2 inhibitors may tip the natural balance between prothrombotic thromboxane A2 (TxA2) and antithrombotic prostacyclin (PGI2) potentially increasing the possibility of a thrombotic cardiovascular event (17-19).”
BackgroundCombe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Klareskog, L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044354 · Cited by 786
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Familial adenomatous polyposis
Galiatsatos, P., & Foulkes, W. D. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00375.x · Cited by 757
“inhibitors in adenoma chemoprevention trials are cause for concern (155, 156), and make the use of these drugs for this”
BackgroundPatrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
“A year later a large randomized controlled trial of rofecoxib confirmed the elevated risk in a healthier and younger population.(40) The additional estimation error of OREC from the validation study can be incorporated in the overall error term.”
BackgroundSostres, C., Gargallo, C. J., Arroyo, M. T., & Lanas, A. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.11.005 · Cited by 685
ASAS/EULAR recommendations for the management of ankylosing spondylitis
Zochling, J., van der Heijde, D., Burgos-Vargas, R., Collantes, E., Davis, J. C., Dijkmans, B., Dougados, M., Géher, P., Inman, R. D., Khan, M. A., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.041137 · Cited by 702
Familial adenomatous polyposis
Half, E., Bercovich, D., & Rozen, P. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-22 · Cited by 596
“gastrointestinal toxicity, the long-term use of COX-2 inhibitors in the setting of CRC prevention carries a risk, albeit small, of serious cardiovascular complications [112].”
BackgroundUsing Recovery Modalities between Training Sessions in Elite Athletes: Does it Help?
Barnett, A. (2006) · Sports Medicine · doi:10.2165/00007256-200636090-00005 · Cited by 593
An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong, C. K. S., Lirk, P., Tan, C. H., & Seymour, R. A. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.698 · Cited by 587
Therapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
“However, the current controversy surrounding the association of long-term high-dose COX-2 inhibitor use with an elevated risk of cardio vascular events (Bresalier et al., 2005) indicates that alternative drugs or molecular targets will need to be identified.”
Shimizu, T. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145616 · Cited by 576
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., & Hong, Y. (2008) · Circulation · doi:10.1161/circulationaha.107.188965 · Cited by 552
Structural and Functional Basis of Cyclooxygenase Inhibition
Blobaum, A. L., & Marnett, L. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613166 · Cited by 550
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
Self-citationBruyère, O., Cooper, C., Pelletier, J.-P., Branco, J., Luisa Brandi, M., Guillemin, F., Hochberg, M. C., Kanis, J. A., Kvien, T. K., Martel-Pelletier, J., et al. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.05.014 · Cited by 515
“Concomitant use of low-dose aspirin did not attenuate the increased cardiovascular risk associated with COX-2-selective NSAIDs in placebo-controlled trials [76,77], while observational”
BackgroundLanas, A., García-Rodríguez, L. A., Arroyo, M. T., Gomollón, F., Feu, F., González-Pérez, A., Zapata, E., Bástida, G., Rodrigo, L., Santolaria, S., et al. (2006) · Gut · doi:10.1136/gut.2005.080754 · Cited by 524
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
“However, an increased risk for severe cardiovascular events was soon recognized [44, 45], which resulted in the withdrawal of rofecoxib in 2004.”
BackgroundAngiogenesis and chronic inflammation: cause or consequence?
Costa, C., Incio, J., & Soares, R. (2007) · Angiogenesis · doi:10.1007/s10456-007-9074-0 · Cited by 504
“However, inhibition of COX-2 and synthesis of eicosanoids in atherosclerotic patients resulted in increased incidence of cardiovascular disorders [222].”
BackgroundSignalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492
Making trials matter: pragmatic and explanatory trials and the problem of applicability
Treweek, S., & Zwarenstein, M. (2009) · Trials · doi:10.1186/1745-6215-10-37 · Cited by 482
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 478
Serhan, C. N. (2005) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.002 · Cited by 454
Chan, C.-W., & Peng, P. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01089.x · Cited by 452
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
“However, the 18-month Adenomatous Polyp Prevention On Vioxx ® (APPROVe) trial designed to investigate the efficacy of rofecoxib in preventing the recurrence of colon polyps was stopped early because of an increase in adverse cardiovascular events [93].”
BackgroundGislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Køber, L., Madsen, M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.616219 · Cited by 447
Postoperative pain—from mechanisms to treatment
Pogatzki-Zahn, E. M., Segelcke, D., & Schug, S. A. (2017) · PAIN Reports · doi:10.1097/pr9.0000000000000588 · Cited by 407
Chemophototherapy: An Emerging Treatment Option for Solid Tumors
Luo, D., Carter, K. A., Miranda, D., & Lovell, J. F. (2017) · Advanced Science · doi:10.1002/advs.201600106 · Cited by 436
A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas
Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., Bolognese, J. A., Oxenius, B., Horgan, K., Loftus, S., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.079 · Cited by 433
Self-citationConaghan, P. G. (2012) · Rheumatology International · doi:10.1007/s00296-011-2263-6 · Cited by 407
“The Adenomatous Polyp Prevention On Vioxx (APPROVe) study found that rofecoxib 25 mg/day was associated with an increased RR of thrombotic events compared with placebo in patients with a history of colorectal adenomas after 18 months of treatment and an increased risk of myocardial infarction after 15 months of treatm…”
BackgroundHoes, J. N., Jacobs, J. W. G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E. H., Cutolo, M., Da Silva, J. A. P., Esselens, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072157 · Cited by 411
da Costa, B. R., Pereira, T. V., Saadat, P., Rudnicki, M., Iskander, S. M., Bodmer, N. S., Bobos, P., Gao, L., Kiyomoto, H. D., Montezuma, T., et al. (2021) · BMJ · doi:10.1136/bmj.n2321 · Cited by 377
“56 57 In this trial, patients were randomly allocated to receive one 25 mg tablet of rofecoxib each day (the maximum recommended long term daily dose) or a placebo tablet each day for three years.”
BackgroundMethodCardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
An overview of treatment approaches for chronic pain management
Hylands-White, N., Duarte, R. V., & Raphael, J. H. (2017) · Rheumatology International · doi:10.1007/s00296-016-3481-8 · Cited by 387
A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices
Prasad, V., Vandross, A., Toomey, C., Cheung, M., Rho, J., Quinn, S., Chacko, S. J., Borkar, D., Gall, V., Selvaraj, S., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.05.012 · Cited by 381
Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention
Vonkeman, H. E., & van de Laar, M. A. F. J. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.08.001 · Cited by 365
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Singh, G., Fort, J. G., Goldstein, J. L., Levy, R. A., Hanrahan, P. S., Bello, A. E., Andrade-Ortega, L., Wallemark, C., Agrawal, N. M., Eisen, G. M., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.054 · Cited by 335
Huijbers, A., Tollenaar, R. A. E. M., v Pelt, G. W., Zeestraten, E. C. M., Dutton, S., McConkey, C. C., Domingo, E., Smit, V. T. H. B. M., Midgley, R., Warren, B. F., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds246 · Cited by 337
Prostaglandin E2 and Pain-An Update
Kawabata, A. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1170 · Cited by 332
Chen, Y., Jobanputra, P., Barton, P., Bryan, S., Fry-Smith, A., Harris, G., & Taylor, R. (2008) · Health Technology Assessment · doi:10.3310/hta12110 · Cited by 339
Harris, R. E. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-8049-8 · Cited by 329
Schjerning Olsen, A.-M., Fosbøl, E. L., Lindhardsen, J., Folke, F., Charlot, M., Selmer, C., Lamberts, M., Bjerring Olesen, J., Køber, L., Hansen, P. R., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004671 · Cited by 335
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 332
Adiponectin actions in the cardiovascular system
HOPKINS, T., OUCHI, N., SHIBATA, R., & WALSH, K. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.009 · Cited by 327
“Recent clinical trials reveal that treatment with selective COX-2 inhibitors resulted in an increased risk for cardiovascular complications [104,105], further implicating a role of COX-2 in protection against ischemia induced injury.”
BackgroundClinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Platelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
Ungprasert, P., Cheungpasitporn, W., Crowson, C. S., & Matteson, E. L. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.008 · Cited by 322
“A superior GI safety profile of specific COX-2 inhibitors has been demonstrated in several randomized controlled trials and epidemiological studies [4–7] though this benefit is offset by the increased risk of serious cardiovascular events [8,9].”
BackgroundNonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
NSAIDs and Cancer Prevention: Targets Downstream of COX-2
Cha, Y. I., & DuBois, R. N. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131253 · Cited by 308
Regulation of inflammation in cancer by eicosanoids
Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.08.004 · Cited by 303
Hypertension in rheumatoid arthritis
Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., & Kitas, G. D. (2008) · Rheumatology · doi:10.1093/rheumatology/ken159 · Cited by 303
Pharmacovigilance: methods, recent developments and future perspectives
Härmark, L., & van Grootheest, A. C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0475-9 · Cited by 289
“The decision to withdraw rofecoxib was made after the safety monitoring board of the APPROVe trial found an increased risk of cardiovascular (CV) events in patients treated with rofecoxib compared to placebo [2].”
BackgroundArfè, A., Scotti, L., Varas-Lorenzo, C., Nicotra, F., Zambon, A., Kollhorst, B., Schink, T., Garbe, E., Herings, R., Straatman, H., et al. (2016) · BMJ · doi:10.1136/bmj.i4857 · Cited by 290
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
Howe, L. R. (2007) · Breast Cancer Research · doi:10.1186/bcr1678 · Cited by 293
“Less propitiously, some trials also identified increased cardiovascular risk associated with COXib use [70,71].”
BackgroundGislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbøl, E. L., Sørensen, R., Folke, F., Buch, P., Gadsbøll, N., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.525 · Cited by 295
Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1211 · Cited by 289
Desai, S. J., Prickril, B., & Rasooly, A. (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1446091 · Cited by 274
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
“Variables of note include (1) the risk”
BackgroundLi, J., Kuang, Y., Gao, Y., Du, X., Shi, J., & Xu, B. (2013) · Journal of the American Chemical Society · doi:10.1021/ja310019x · Cited by 283
Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview
Chan, A. T., Arber, N., Burn, J., Chia, W. K., Elwood, P., Hull, M. A., Logan, R. F., Rothwell, P. M., Schrör, K., & Baron, J. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0391 · Cited by 276
“Despite this demonstrated efficacy, a dosedependent association with CV events that was uncovered in these studies hampers the routine use of these agents for widespread chemoprevention (96-99).”
Self-citationTreatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer
Feagins, L. A., Souza, R. F., & Spechler, S. J. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.44 · Cited by 274
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.636746 · Cited by 273
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.